HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

NAActive, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

May 31, 2028

Conditions
Metastatic Cancer
Interventions
OTHER

Tumor and Blood sample collection

"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"

Trial Locations (15)

11407

Hospital Universitario de Jerez, Jerez de la Frontera

28046

Hospital La Paz, Madrid

30120

Hospital Universitario Virgen de la Arrixaca, Murcia

38320

Hospital Universitario de Canarias, Santa Cruz de Tenerife

46009

Instituto Valenciano de Oncología (IVO), Valencia

Unknown

ICO Badalona, Badalona

H.Univ. Arnau de Vilanova de Lleida, Lleida

Hospital Virgen de Macarena, Seville

Hospital Universitari Vall d' Hebron, Barcelona

ICO Hospitalet, Barcelona

Hospital Universitario 12 de octubre, Madrid

Hospital Virgen de la Victoria, Málaga

Hospital Universitario Virgen del Rocio, Seville

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER